Decision Resources Research Reports

Title	Published	Price
Rochester, NY Market Overview By: Decision Resources Healthcare Market Overviews Market Overviews give a detailed analysis of 75 of the most important healthcare markets in the United States, including the major players among hospitals and health systems, physician groups and health plans, as \| more...	10/26/2006	$735.00
Putting Promotion in Perspective: Part I - A Strategic Overview By: Decision Resources Promotional expenditure is the principal area of cost for the pharmaceutical industry. Fully expressed, these costs far outweigh R&D expenditure, yet they tend to receive less attention from pharmaceutical and biotechnology companies than other cost \| more...	6/30/2005	$1,012.50
Putting Promotion in Perspective: Part II - Timing, Mix, and Impact By: Decision Resources Controversy surrounds direct-to-consumer (DTC) advertising, the segment of promotional activity that we focus on in Part II of “Putting Promotion in Perspective,” in which we expand our analysis of the issues outlined in Part I. \| more...	9/27/2005	$1,012.50
Advances in the Treatment of Serious Systemic Fungal Infections - An Update By: Decision Resources Opportunistic fungal infections are a major problem in immunocompromised patients. In recent years, the number of patients with severe immunosuppression has risen dramatically as a result of advances in the treatment of HIV/AIDS, cancer, and \| more...	3/18/2005	$1,012.50
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market By: Decision Resources Antibacterial resistance has always been an important driver of innovation for new antibacterial agents. Over the past 10-15 years, resistance to antibacterials in the hospital setting has risen dramatically. Although they are niche segments with \| more...	4/1/2005	$1,012.50
Impact of Bariatric Surgeries on the Obesity Pharmaceutical Market By: Decision Resources For morbidly obese patients, bariatric surgery is an increasingly attractive option after more traditional weight loss methods have failed. The lack of long-term efficacy and the modest weight loss associated with currently marketed anti-obesity drugs—particularly \| more...	4/21/2005	$1,012.50
Outlook for Cancer Vaccine Development By: Decision Resources The incorporation of monoclonal antibodies into oncology therapy regimens has created an environment of acceptance toward new biologic therapies. Developers of cancer vaccines will be able to use this acceptance to establish these treatments as \| more...	5/23/2005	$1,012.50
Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers By: Decision Resources Biomarkers have the potential to play a valuable role in simplifying the pharmaceutical development process. They can be used to identify patient populations, improve dosing regimens, and alter delivery routes to adjust responses. This report \| more...	6/16/2005	$1,012.50
Can Biomarkers Increase the R&D Productivity By: Decision Resources Biotechnology and pharmaceutical companies are increasingly looking to biomarkers to help them increase R&D productivity and clinical trial success rates. They are using biomarkers to eliminate toxic compounds early in the development process and to \| more...	10/18/2005	$1,012.50
Progress in RNA-Based Therapeutics By: Decision Resources The field of nucleic acid-based therapeutics ranges from gene therapy technologies for replacing defective or missing genes to gene-blocking or gene-silencing technologies for preventing the expression of deleterious genes. RNA-based therapeutics are a relatively new \| more...	8/4/2005	$1,012.50
Nanotechnology for Drug Discovery and Drug Design By: Decision Resources Nanotechnology, a field of science and technology that aims to control matter at the atomic, molecular, and macromolecular level, potentially has far-reaching and paradigm-shifting implications for biology, drug discovery, and medical technologies. The discipline has \| more...	8/11/2005	$1,012.50
Knowledge Management Tools for Drug Discovery By: Decision Resources Pharmaceutical companies are investing in new R&D technologies in the hope that they will accelerate research and, ultimately, improve both productivity and profitability. Before these technologies can boost profitability, however, the data they produce must \| more...	6/15/2005	$1,012.50
Obesity Drug Discovery: Success and Challenges for a New Pharmaceutical Market By: Decision Resources In recent years, obesity has become a major health problem for many postindustrial societies, so much so that in 2004, the United States Health and Human Services declared obesity to be a disease. Obesity poses \| more...	6/15/2005	$1,012.50
Spectrum Quarterly Deal Review - Fourth Quarter 2004 By: Decision Resources The life sciences industry closed 2004 with a robust fourth quarter. The industry demonstrated its vitality by attracting more than $10 billion in financing, owing mostly to a thoroughly rebounded debt financing environment. Also contributing \| more...	2/28/2005	$1,012.50
Spectrum Quarterly Deal Review - First Quarter 2005 By: Decision Resources Having ended 2004 with a bang, the life sciences industry started 2005 with a whimper. The financial woes within the industry mirrored the weak performance of broader financial markets during the first quarter. The damage, \| more...	6/27/2005	$1,012.50
Spectrum Quarterly Deal Review - Second Quarter 2005 By: Decision Resources The second quarter of 2005 proved both promising and foreboding for the life sciences industry. On one hand, life sciences securities, notably biotechnology companies, experienced a sharp rebound from their first quarter drop. Other important \| more...	6/30/2005	$1,012.50
Future of VLA-4 Antagonist Drugs and Implications for the Regulatory Process By: Decision Resources In March 2005, in response to the development of three cases of a rare opportunistic infection in patients taking Biogen Idec and Elan’s monoclonal antibody (MAb) natalizumab (Tysabri), the FDA decided to place a clinical \| more...	6/28/2005	$1,012.50
Improved Diagnostic and Prognostic Tools for Rheumatoid Arthritis: Unmet Needs in a Changing Market By: Decision Resources According to recent clinical studies, the key to achieving optimal outcomes in rheumatoid arthritis (RA) is to diagnose and treat it as early as possible. The need to develop more-sensitive and more-specific markers for early-stage \| more...	3/21/2005	$1,012.50
Threats and Opportunities Facing the PSA Testing Marketplace By: Decision Resources Dramatic increases in the number of men screened for prostate cancer (CaP) and several key market drivers related to prostate-specific antigen (PSA) testing represent healthy market potential for companies active in the screening and diagnosis \| more...	4/1/2005	$1,012.50
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part 1: Optimizing the Comarketing Plan By: Decision Resources With so many targeted therapies requiring the use of a diagnostic coming to market, comarketing of diagnostics and therapeutics will become routine. This report (the first in a series of two) addresses key frameworks on \| more...	4/29/2005	$1,012.50
Emerging Diagnostic Markers in Alzheimer’s Disease By: Decision Resources Currently, Alzheimer’s disease (AD) is diagnosed based on patient clinical history and exclusion of other neurological disorders. Because early signs of AD are hard to distinguish from normal signs of aging, most patients are not \| more...	6/14/2005	$1,012.50
Applications of Stem Cells in Drug Discovery By: Decision Resources Stem cells are unspecialized cells that can differentiate into numerous types of specialized cells with specific functions. Diseases and disorders that might benefit from stem-cell research include Parkinson’s, Alzheimer’s, diabetes, cancer, heart disease, spinal cord \| more...	1/25/2005	$1,012.50
Investment and Business Trends in Biotechnology: 2004 in Review By: Decision Resources This report covers investment and business trends in Biotechnology for \| more...	3/16/2005	$1,012.50
Disease Management in the 21st Century By: Decision Resources Disease management (DM) programs were pioneered by the pharmaceutica industry in the early 1990s, but beginning in 1996, manufacturer-sponsored DM programs began to lose ground as employer-sponsored health plans, recognizing the value of DM— improved \| more...	11/10/2005	$1,012.50
Discoveries and Challenges in Early-Stage Apoptosis By: Decision Resources Apoptosis, the major and best-studied pathway of programmed cell death, plays an important role in embryonic development, the immune system, and protection against mutations and cancer. As such, it has become an intriguing focus of \| more...	11/14/2005	$1,012.50
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4